Parkinson's disease (PD) was first described by James Parkinson in 1817 and remains one of the most important disabling illnesses of later life.
may be because physicians or nurses concentrate more on motor aspects, there is unawareness that NMS are related to PD or the symptoms are not declared to healthcare professionals. 2 Recent work by the Parkinson's Disease Non-motor Group (PD-NMG) has led to the validation of the first comprehensive clinic-based self-completed NMS questionnaire (NMSQuest, see Table 1 ), 3 as well as a scale (the NMS scale) that allows easy identification of NMS by the physician. 3, 4 Patients often find the NMS of PD more disturbing than the motor symptoms. Indeed, NMS dominate the clinical picture of advanced PD and contribute to severe disability, impaired quality of life and shortened life expectancy. In contrast to the dopaminergic (motor) symptoms, for which treatment is available, NMS are often poorly recognised and inadequately treated. Some NMS -including depression, constipation, pain, genito-urinary problems and sleep disorders -can be improved with available treatments. Other NMS can be more refractory and need the introduction of novel nondopaminergic drugs. The development of treatments that can slow or prevent the progression of PD and its multicentric neurodegeneration provides the best hope of curing NMS. 4 NMS correlate with advancing age and disease severity, although some NMS -such as olfactory problems, constipation, depression and rapid eye movement (REM) disorder -can occur early in the disease. 2 The prevalence of NMS as a whole is inadequately documented because there are insufficient adequately powered community-based studies on prevalence, effect and treatment efficacy in relation to NMS; there is thus a need for large, well-designed prospective studies. The role and effect of the NMS complex during the disease course has been examined in a prospective study of patients with PD followed up for 15-18 years, which showed that non-levodopa-responsive NMS are the most disabling feature of the disease. 5 A wide spectrum of NMS have been described in PD, as shown in Table 2 .
Continuous Dopaminergic Stimulation
Continuous dopaminergic stimulation (CDS; see Table 3 ) is a relatively modern concept that has been shown to reduce the severity and incidence of dyskinesias based on the fact that pulsatile delivery of dopamine to the deafferented dopamine receptors in the striatum is likely to be dyskinesogenic. 9 CDS may prevent or reverse motor complications resulting from reduced priming of the basal ganglia for involuntary movements compared with agents that produce pulsatile stimulation. 10 Non-motor Symptoms in Late-stage Parkinson's DiseaseIs Continuous Dopaminergic Stimulation Beneficial? 
